The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease
- Publication Type:
- Journal Article
- Citation:
- British Journal of Pharmacology, 2017, 174 (1), pp. 3 - 14
- Issue Date:
- 2017-01-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| Wong BJP 2016.pdf | Published Version | 696.2 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
© 2016 The British Pharmacological Society The SPARC (secreted protein acidic and rich in cysteine) protein is matricellular molecule regulating interactions between cells and their surrounding extracellular matrix (ECM). This protein thus governs fundamental cellular functions such as cell adhesion, proliferation and differentiation. SPARC also regulates the expression and activity of numerous growth factors and matrix metalloproteinases essential for ECM degradation and turnover. Studies in SPARC-null mice have revealed a critical role for SPARC in tissue development, injury and repair and in the regulation of the immune response. In the lung, SPARC drives pathological responses in non-small cell lung cancer and idiopathic pulmonary fibrosis by promoting microvascular remodelling and excessive deposition of ECM proteins. Remarkably, although chronic airway conditions such as asthma and chronic obstructive pulmonary disease (COPD) involve significant remodelling in both the airway and vascular compartments, the role of SPARC in these conditions has thus far been overlooked. In this review, we discuss the role of SPARC in lung cancer and pulmonary fibrosis, as well as potential mechanisms by which it may contribute to the disease process in asthma and COPD.
Please use this identifier to cite or link to this item: